Brain Markers of Depression Vulnerability: the Case of Prefrontal Haemodynamic Response

Sponsor
Dr Georg Kranz (Other)
Overall Status
Recruiting
CT.gov ID
NCT05427578
Collaborator
(none)
60
1
29
2.1

Study Details

Study Description

Brief Summary

Functional near infrared spectroscopy (fNIRS) offers a cheap and reliable tool to investigate prefrontal brain activation in the healthy and diseased human brain. As such, fNIRS bears great potential as a diagnostic tool for clinical practice. Research indicates that fNIRS, together with a relatively simple task to activate the prefrontal cortex, the so-called verbal fluency task (VFT), elucidates prefrontal dysfunction in major depressive disorder (MDD). This finding can potentially serve as an imaging marker for disease pathology, even when depressive symptoms are absent. Indeed, recent research also suggests prefrontal dysfunction in fully remitted MDD (rMDD). Prefrontal haemodynamic responses may therefore serve as a trait marker for MDD vulnerability.

This study aims to investigate the haemodynamic response in rMDD, healthy participants with increased MDD risk (HCr; having a 1st-degree relative with MDD), and low-risk healthy participants (HCnr; having no 1st-degree relatives with MDD) using fNIRS. The investigators hypothesize lower prefrontal reactivity in HCr compared to HCnr, and lowest prefrontal reactivity in rMDD compared to HCnr.

This study has the potential to elucidate the neuronal underpinnings of depression vulnerability in the absence of symptoms that are sometimes considered a confounding factor when it comes to studying the biological encoding of depression.

Condition or Disease Intervention/Treatment Phase
  • Other: fNIRS measurement

Detailed Description

Healthy participants with a high risk of MDD (HCr), healthy participants with a low risk of MDD (HCnr) and rMDD participants will be included in this study.

Prefrontal haemodynamic response will be measured in all participants during the verbal fluency test (VFT) using 52 channels fNIRS. The VFT involves two neural conditions, one positive condition, and one negative condition.

Both the neuroimage change and the behavioral outcomes of VFT will be compared within-group and among groups. The correlation between the neuroimage change and the behavioral outcomes will be analyzed as well.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Brain Markers of Depression Vulnerability: the Case of Prefrontal Haemodynamic Response
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Remitted depression

Patients in full remission of a major depressive disorder (rMDD)

Other: fNIRS measurement
measurement using functional near-infrared spectroscopy

Healthy participants at risk

Healthy participants with increased MDD risk (having a 1st-degree relative with MDD)

Other: fNIRS measurement
measurement using functional near-infrared spectroscopy

Healthy participants low risk

Healthy participants with low MDD risk (having no 1st-degree relatives with MDD)

Other: fNIRS measurement
measurement using functional near-infrared spectroscopy

Outcome Measures

Primary Outcome Measures

  1. Oxygenated hemoglobin (HbO) change during VFT [Up to 6 months]

    The HbO change during VFT measuring by fNIRS

Secondary Outcome Measures

  1. Deoxygenated hemoglobin (HbR) change during VFT [Up to 6 months]

    The HbR change during VFT measuring by fNIRS

  2. The VFT outcome [Up to 6 months]

    The number of correct words during VFT

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Mini-mental state examination (MMSE) > 24
Exclusion Criteria:
  • Current diagnosis of psychiatric disorders, such as depression, anxiety, schizophrenia, or autism

  • current or past diagnosis of neurological disorders, such as head injuries, strokes, encephalitis, epilepsy, Parkinson's, or Alzheimer's

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Hong Kong Polytechnic University Hong Kong Hong Kong

Sponsors and Collaborators

  • Dr Georg Kranz

Investigators

  • Principal Investigator: Georg S Kranz, PhD, The Hong Kong Polytechnic University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Georg Kranz, Principal Investigator, The Hong Kong Polytechnic University
ClinicalTrials.gov Identifier:
NCT05427578
Other Study ID Numbers:
  • HSEARS20210323001-01
First Posted:
Jun 22, 2022
Last Update Posted:
Aug 4, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr Georg Kranz, Principal Investigator, The Hong Kong Polytechnic University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2022